Global In-vitro Toxicology Testing Market - 2023-2030

Global In-vitro Toxicology Testing Market - 2023-2030

Global In-vitro Toxicology Testing Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing with a CAGR of XX % during the forecast period 2024-2031.

In vitro models play an important role in the toxicity testing of cosmetics, drugs and pharmaceutical therapies. Advancements in in vitro cell culture have given researchers a viable alternative and/or complement to live animal testing.

In vitro models offer several ethical and economic advantages over animal testing. These assays are being used earlier in toxicity testing pipelines, often to determine risk assessment and/or set up controls that will ultimately spare animal life. The combination of lower-cost and higher throughput assays can help bring products to market faster. Additionally, in vitro models give researchers an advantage in understanding the biological process involved in a toxic response sooner than if they were depending on the visual inspection of a live animal.

Market Dynamics: Drivers and Restraints

Rise in advancements in in-vitro toxicology testing

Technological advancements in in-vitro toxicology testing have made it a preferred method over animal testing. Regulatory agencies are increasingly validating and accepting these methods, boosting the market. In some countries, animal geno-toxicology testing is mandated before marketing certain consumer items, such as genetically modified foods, vaccines, devices, drugs, industrial chemicals, and pesticides.

Additionally, recent advancements in the understanding of stem cell-derived cardiomyocytes have allowed researchers to develop more accurate and reproducible in vitro assays that are based on human cells. Future work in this area hopes to use stem cell-derived cardiomyocytes that have been integrated into three-dimensional structures for an additional layer of drug safety screening.

Furthermore, the in-vitro toxicology testing market is also driven by various other factors like the rise in demand for healthcare services, rise in the government initiatives and others that help the market to grow during the forecast period.

Market Dynamics: Restraint

In vitro toxicity testing is gaining recognition due to animal testing bans in several countries. However, it still needs to demonstrate validity compared to in vivo tests. In vitro tests only determine the mechanism of action of test substances, not their outcomes after metabolism. Although a chemical substance may not be harmful, its metabolites can be detrimental.

Segment Analysis

The global in-vitro toxicology testing market is segmented based on product and service type, toxicity, technology, end-user and region.

The assays from the product and service type segment accounted for approximately 39.7% of the in-vitro toxicology testing market share

The assays from the product and service type segment accounted for approximately 39.7% and are expected to dominate during the forecast period. In vitro toxicity assays are some of the most useful preclinical methods of not only determining a drug’s safety profile but also providing an opportunity for researchers to improve its properties before reaching clinical trials.

In vitro toxicology assays, in silico and chemical testing approaches, are crucial in identifying alternative methods to traditional animal-based toxicity testing. These services support metabolic, toxicokinetic, and bioanalytical investigations with qualitative and quantitative data, promoting the 3Rs (Replacement, Reduction, and Refinement) approach.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors like acquisitions by companies, rising government funding for research of therapeutics, increased healthcare expenditure, advanced infrastructure & processes for drug discovery and strong regulatory framework for approval has increased the demand as well as adoption on in-vitro testing methods in this region’s market.

For instance, in March 2023, Agilent Technologies, Inc. (US) acquired e-MSion (US). Through this acquisition, Agilent will integrate the e-MSion's ExD cell into its portfolio of advanced workflows, instruments, and analytical solutions for biotherapeutic characterization and development.

Moreover, in September 2022, ioIVT disclosed the successful acquisition of XenoTech, showcasing its dedication to offering extensive research models and services to biopharmaceutical customers for improved drug development and diagnostic research.

COVID-19 Impact Analysis

The COVID-19 pandemic had a substantial impact on the overall market resulting in limitations of movement and restrictions due to which the market observed a short-term decline in growth. However, as there were multiple drug discovery processes, various drug development programs & and high research activities, the market demand for in-vitro toxicology testing accelerated eventually.

Market Segmentation

By Product & Service Type
• Assays
Bacterial Toxicity Assays
Enzyme Toxicity Assays
Cell-Based ELISA & Western Blotting Assays
Receptor Binding Assays
Others
• Consumables
• Services
• Equipment’s
• Software

By Toxicity
• Cytotoxicity
• Gene Toxicity
• Cardiotoxicity
• Hepatotoxicity
• Ophthalmic Toxicity
• Others

By Technology
• Cell Culture
• High Throughput Screening
• Toxicogenomics

By End User
• Pharmaceutical and Biopharmaceutical Companies
• Consumer Care and Food Industry
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Charles River Laboratories International, Inc., SGS S.A., Eurofins Scientific, Laboratory Corporation of America Holdings, Evotec S.E., Agilent Technologies, Inc., Catalent, Inc., Bio-Rad Laboratories, Inc., BioIVT, Gentronix and among others.

Key Developments

 In January 2023, Eurofins Scientific expanded its presence in India with the establishment of a new, fully equipped, state-of-the-art laboratory campus in Genome Valley, Hyderabad. The lab will support pharma and biotech companies in the areas of synthetic organic chemistry, analytical R&D, bioanalytical services, in vivo pharmacology, safety toxicology, and formulation R&D.

 In January 2021, Charles River stated a partnership with Cypre, Inc., for the expansion of services of 3D in-vitro models for immunotherapy treatment of cancer as well as targeted therapy drug screening. This partnership enabled the company to access Cypre’s patented 3D hydrogel technology or Falcon-X to expand Charles River’s services.

Why Purchase the Report?
• To visualize the global in-vitro toxicology testing market segmentation based on product and service type, toxicity, technology, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of in-vitro toxicology testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global in-vitro toxicology testing market report would provide approximately 69 tables, 70 figures and 183 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies